Pokorny R M, Hunt L, Galandiuk S
Department of Surgery, University of Louisville School of Medicine, KY 40292, USA.
Dig Surg. 2000;17(3):209-15. doi: 10.1159/000018853.
BACKGROUND/AIMS: Many tumor markers have been utilized in the follow-up care of colorectal cancer patients. No marker, however, has proven reliably accurate in detecting recurrent disease.
The strengths and weaknesses of currently available tumor markers are reviewed, with attention to related cost and efficacy.
Tumor antigens, enzymes, and genetic markers have been used as tumor markers. CEA and CA 19.9 are the most widely utilized; however, genetic markers are the most promising for the future.
Currently available markers have significant limitations. Development of genetic markers may greatly enhance our ability to predict prognosis and the need for adjuvant therapy. Marker-guided therapy may play an increasing role in this disease.
背景/目的：许多肿瘤标志物已用于结直肠癌患者的随访。然而，尚无标志物在检测复发疾病方面被证明具有可靠的准确性。
回顾了目前可用肿瘤标志物的优缺点，并关注相关成本和疗效。
肿瘤抗原、酶和基因标志物已被用作肿瘤标志物。癌胚抗原（CEA）和糖类抗原19-9（CA 19.9）应用最为广泛；然而，基因标志物在未来最具前景。
目前可用的标志物有显著局限性。基因标志物的开发可能会大大提高我们预测预后和辅助治疗需求的能力。标志物引导的治疗可能在这种疾病中发挥越来越重要的作用。
